Cornejo also explains potential positive and adverse reactions to the medication, allowing for informed consent
Areas such as deep abdominal fat (visceral adipose tissue) and lower body subcutaneous fat often demonstrate resistance to traditional fat loss approaches due to lower concentrations of beta-adrenergic receptors and higher concentrations of anti-lipolytic alpha-2 adrenergic receptors
Our 2025 analysis identified early signs of reduced consumption among GLP-1 users
But, it requires consistency, time, and effort to see results
IGF-1 LR3 bypasses that entire regulatory sequence and acts directly on tissue-level IGF-1 receptors, which is why research describes its signaling onset as faster and more direct than secretagogue-based approaches, though also more potent at the receptor level
doi: 10.1111/j.1740-8261.1997.tb00874.x